Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: Solid Tumor/Phase INCT ID: NCT01940796
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-239
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
Conducting Institutions: Massachusetts General Hospital
Overall PI: Yi-Bin Chen, MD,
Massachusetts General Hospital
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100